MyMD Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018 - 2011
Net Income	-8.22	-15.2	-29.89	-9.49	-3.89	Upgrade
Depreciation & Amortization	0	0	0	0.02	0.07	Upgrade
Share-Based Compensation	2.91	0.34	15.04	2.86	0.39	Upgrade
Other Operating Activities	-11.89	2.59	-4.66	1.94	0.35	Upgrade
Operating Cash Flow	-12.98	-12.27	-19.52	-4.66	-3.07	Upgrade
Capital Expenditures	0	0	0	0	0.01	Upgrade
Acquisitions	0	0	1.38	0	0	Upgrade
Change in Investments	1.85	6.91	18.47	0	-3.95	Upgrade
Investing Cash Flow	1.85	6.91	19.85	0	-3.94	Upgrade
Share Issuance / Repurchase	0	5.55	1.19	1.98	6.97	Upgrade
Debt Issued / Paid	0	0	-1.12	2.7	0	Upgrade
Other Financing Activities	13.07	-	-	-	-	Upgrade
Financing Cash Flow	13.07	5.55	0.07	4.68	6.97	Upgrade
Net Cash Flow	1.93	0.19	0.41	0.01	-0.05	Upgrade
Free Cash Flow	-12.98	-12.27	-19.52	-4.66	-3.07	Upgrade
Free Cash Flow Per Share	-8.42	-9.48	-16.72	-4.96	-300.46	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).